Dutch biotech at­tracts J&J sup­port for can­cer pipeline in $21M Se­ries A

Flindr Ther­a­peu­tics has se­cured €20 mil­lion ($21 mil­lion) in a Se­ries A raise aimed at ad­vanc­ing its lead pro­gram through an IND ap­pli­ca­tion and grow­ing its pipeline of small-mol­e­cule can­cer drugs.

The Dutch biotech’s lead drug can­di­date in­hibits RNF31, a pro­tein-sta­bi­liz­ing E3 ubiq­ui­tin lig­ase. The mech­a­nism had “high­ly promis­ing ac­tiv­i­ty” in pre­clin­i­cal ovar­i­an can­cer and B cell lym­phoma mod­els, Flindr said, adding it has iden­ti­fied bio­mark­ers that could help iden­ti­fy pa­tients most like­ly to re­spond.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER